Abstract Body

Background

Hepatitis C virus (HCV) prevalence among pregnant people in the U.S. increased ten-fold over the past two decades, affecting nearly 0.5% of pregnancies in 2019. While direct-acting antivirals (DAAs) are highly effective, current guidelines diverge. The Infectious Diseases Society of America/American Association for the Study of Liver Diseases endorse shared decision-making, while the American College of Obstetricians and Gynecologists advises deferring treatment until after breastfeeding. Yet, postpartum linkage to HCV care is poor, with only 6% initiating DAAs within 6 months of delivery. We hypothesized that treatment of HCV during pregnancy would be cost-effective compared to the status quo.

Methods

To compare lifetime clinical and economic outcomes between treating HCV during pregnancy and deferring treatment until after breastfeeding, we expanded a Monte Carlo microsimulation model of HCV care (HEP-CE) to include pregnancies (PreVenT) and simulated 29,000 pregnant individuals with HCV and subsequent HCV care delivery. Strategies included: (1) status quo of deferred treatment until after breastfeeding and (2) treatment during pregnancy. We derived parameter inputs from published literature and local programmatic data on HCV treatment acceptance during pregnancy (75%). Outcomes included transmission to infants, cases of cirrhosis, liver-related mortality, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We assumed a healthcare perspective and discounted all costs at 3% annually.

Results

Compared with status quo, treatment during pregnancy led to a 65% reduction in the number of infants with perinatal HCV infection (3,872 vs. 1,343), a 65% reduction in lifetime cirrhosis cases (12,876 vs. 4,499), a 68% reduction in liver-related deaths (10,673 vs. 3,438), and increased QALYs (12.0 vs. 13.3). The ICER for treatment during pregnancy was $13,400 per QALY gained compared to the status quo. The main driver of clinical and cost-effectiveness was co-localized HCV treatment in prenatal settings, reducing loss to follow-up compared to the status quo.

Conclusions

Treatment of HCV during pregnancy is cost-effective—falling well below the commonly accepted U.S. willingness-to-pay-threshold of $50,000–$150,000/QALY. Treatment during pregnancy substantially reduces infant HCV infections as well as long-term maternal liver-related morbidity and mortality compared with the status quo, largely attributable to significant loss to follow-up after delivery.